Cochrane · systematic review · CD003279
Treatment for Lambert‐Eaton myasthenic syndrome
Keogh, M, Sedehizadeh, S, Maddison, P · Cochrane Database of Systematic Reviews · 2011 · Cochrane Library
NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 33.3%High 2 · 66.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
3,4‐Diaminopyridine compared to placebo for LEMS
Population: participants with Lambert‐Eaton myasthenic syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improvement in muscle strength (QMG score) Scale from: 0 to 39 3,4‐Diaminopyridine vs placebo | no estimate extracted | 2 studies · 40 participants | Moderate |
Improvement in mean CMAP amplitude (mV) 3,4‐Diaminopyridine vs placebo | no estimate extracted | 4 studies · 94 participants | High |
Adverse events 3,4‐Diaminopyridine vs placebo | no estimate extracted | 4 studies · 42 participants | High |